Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus

doi:10.1084/jem.175.1.297

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Gmelig-Meyling, F.
	Articles by Steinberg, A. D.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Gmelig-Meyling, F.
	Articles by Steinberg, A. D.


Social Bookmarking

	What's this?

ARTICLES

Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus

F Gmelig-Meyling, S Dawisha and AD Steinberg
Cellular Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, Maryland 20892.

The frequency of mutant T cells (FMC) in blood lymphocytes from patients with systemic lupus erythematosus (SLE) was measured by growing cells in the presence and in the absence of 6-thioguanine. Patients with SLE had a spectrum of FMC ranging from normal to about 100 times normal. This high FMC among cells from SLE patients appears to reflect excessive in vivo activation and proliferation during the course of the disease. This represents the first demonstration of such a T cell abnormality in SLE; it supports the hypothesis that SLE T cells demonstrate increased in vivo division and/or survival.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Lawson, B. R., Baccala, R., Song, J., Croft, M., Kono, D. H., Theofilopoulos, A. N. (2004). Deficiency of the Cyclin Kinase Inhibitor p21(WAF-1/CIP-1) Promotes Apoptosis of Activated/Memory T Cells and Inhibits Spontaneous Systemic Autoimmunity. JEM 199: 547-557 [Abstract] [Full Text]
Takada, K, Illei, G G, Boumpas, D T (2001). Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10: 154-161 [Abstract]
Sandhu, J. K., Privora, H. F., Wenckebach, G., Birnboim, H. C. (2000). Neutrophils, Nitric Oxide Synthase, and Mutations in the Mutatect Murine Tumor Model. Am. J. Pathol. 156: 509-518 [Abstract] [Full Text]
Ohtsuka, K., Gray, J. D., Stimmler, M. M., Toro, B., Horwitz, D. A. (1998). Decreased Production of TGF-{beta} by Lymphocytes from Patients with Systemic Lupus Erythematosus. J. Immunol. 160: 2539-2545 [Abstract] [Full Text]
Hanna, A. N., Waldman, W. J., Lott, J. A., Koesters, S. C., Hughes, A. M., Thornton, D. J. (1997). Increased alkaline phosphatase isoforms in autoimmune diseases. Clin. Chem. 43: 1357-1364 [Abstract] [Full Text]
Ansari, A. A., Mayne, A., Sundstrom, J. B., Gravanis, M. B., Kanter, K., Sell, K. W., Villinger, F., Siu, C. O., Herskowitz, A. (1995). Frequency of Hypoxanthine Guanine Phosphoribosyltransferase (HPRT-) T Cells in the Peripheral Blood of Cardiac Transplant Recipients : A Noninvasive Technique for the Diagnosis of Allograft Rejection. Circulation 92: 862-874 [Abstract] [Full Text]